Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuClone Starts Trial For Ustekinumab Biosimilar

NeuLara Rival To Stelara Enters Phase I Clinical Trial

Executive Summary

After extensive pre-clinical testing, NeuClone has commenced dosing in a Phase I clinical trial for its Stelara biosimilar candidate, NeuLara.

You may also be interested in...



Formycon Begins Biosimilar Ustekinumab Trial

Formycon has become the latest firm to announce a Phase I trial for a proposed biosimilar ustekinumab rival to Janssen’s Stelara, following hot on the heels of NeuClone.

NeuClone hails Stelara replica

NeuClone says pre-clinical results show the biosimilar of Janssen’s Stelara (ustekinumab) that it is developing with Serum Institute of India matches the psoriasis and Crohn’s disease brand “in both primary amino-acid sequence and three-dimensional folding”. The Australian firm is currently conducting process scale-up ahead of Phase I clinical trials scheduled for next year, while it also intends to meet with “potential commercialisation partners”.

Gene Techno Collaborates With Kishi Kasei On Aflibercept

Gene Techno Science and Kishi Kasei have struck a deal to jointly develop a Japanese aflibercept biosimilar rival to Eylea.

Topics

UsernamePublicRestriction

Register

GB149299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel